Mitochondrial & Metabolic

Humanin

For Research Use Only. Not for Human or Veterinary Use.

Overview

Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), first identified in 2001 for its neuroprotective activity and encoded within the mitochondrial 16S ribosomal RNA gene. It has since been characterised in preclinical research as a broad-spectrum cytoprotective peptide — studied against amyloid-β toxicity, apoptosis, oxidative stress, insulin resistance and age-related decline. It is a research compound.

Chemical Profile

PropertyValue
CAS number330936-65-3
ClassMitochondrial-derived peptide (MDP)
Encoding geneMitochondrial 16S rRNA (MT-RNR2)
Amino-acid sequenceH-Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala-OH
One-letter codeMAPRGFSCLLLLTSEIDLPVKRRA (24 aa)
Molecular weight≈ 2687.2 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
Humanin at a glance
Class
Mitochondrial-derived peptide
Gene
Mitochondrial 16S rRNA (MT-RNR2)
Research status
Preclinical; extensive in-vitro / in-vivo
Study routes
SC, IV, intraperitoneal
Half-life
≈ 1–3 h
Key feature
Broad-spectrum anti-apoptotic cytoprotection

Mechanism of Action

Humanin is studied as a cytoprotective peptide that blocks the intrinsic (mitochondrial) apoptosis pathway, principally by binding pro-apoptotic Bax and Bid so they cannot permeabilise the mitochondrial outer membrane. It also engages survival-signalling and stress-response pathways, which underpins its broad protective profile.

ComponentDetail
Primary targetsBax, Bid, IGFBP3
Bax / Bid inhibitionBlocks mitochondrial outer-membrane permeabilization and caspase activation
IGFBP3 bindingModulates IGF-1 signalling
STAT3 activationVia gp130 receptor engagement
Akt pathwayPI3K/Akt survival signalling
Anti-oxidativeStudied for raising SOD2 and catalase
SystemStudied effect
Central nervous systemNeuroprotection against amyloid-β toxicity
CardiovascularProtection against ischemia–reperfusion
MetabolicImproved insulin sensitivity (IGFBP3 modulation)
LongevityExtended lifespan in model organisms

Pharmacology

ParameterValue
Half-life (t½)≈ 1–3 h (plasma, estimated)
Bioavailability (SC)≈ 40–60% (estimated)
Bioavailability (oral)Poor (proteolytic degradation)
Protein bindingModerate (IGFBP3 and albumin)
MetabolismProteolytic degradation
Route of administrationSC, IV, IP (research)
EliminationRenal (peptide fragments)

Research Evidence

Humanin has a large preclinical literature across neuroprotection, metabolism and aging. Representative models and their focus are named below; specific numerical outcomes are not restated here as claims.

ModelResearch focusReference
Primary neuronal cultureProtection against amyloid-β toxicityHashimoto Y, et al. (2001)
Alzheimer’s mouse modelAmyloid burden and behaviourHumanin preclinical literature
Type-2-diabetes mouse modelInsulin sensitivity and glucoseMuzumdar RH, et al.
Model-organism agingLifespan and healthspanHumanin preclinical literature

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Protection against amyloid-β toxicityprimary neuronsHashimoto Y et al., 2001
Improved insulin sensitivitydiabetic miceMuzumdar RH et al.
Cytoprotection via Bax/Bid inhibitionapoptosis modelsHumanin literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 2–8 mg per injection in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Final concentration≈ 5–10 mg/mL
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~7 days
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Local tolerabilityMild injection-site reactions
CytotoxicityNo cytotoxicity observed in cell assays
GenotoxicityNegative in standard assays
GeneralWell tolerated in reported animal studies
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble (> 50 mg/mL)
logP (octanol/water)≈ −2.5 (hydrophilic)
Notable residuesContains one methionine and one cysteine
pH (reconstituted)5.0–6.5
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

Humanin is a 24-residue peptide made by Fmoc solid-phase synthesis. Its four consecutive leucines and its single cysteine and methionine (both oxidation-sensitive) are the points that need careful handling and scavengers at cleavage.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinRink amide MBHA resin
CouplingHBTU / HOBt with DIPEA
Sensitive residuesCys and Met protected against oxidation; scavengers at cleavage
CleavageTFA / TIPS / H₂O with thiol scavengers
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. Contains methionine and cysteine — protect from oxidation during handling.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, reversed-phase TFA/ACN gradientSingle main peak
ESI-MS (positive mode)Identity / massconsistent with the 24-residue peptide
MALDI-TOFMass confirmationconsistent with the 24-residue peptide
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode (consistent with the 24-residue peptide). Contains methionine and cysteine — protect from oxidation during handling.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: Contains methionine and cysteine — protect from oxidation during handling.

Selected References

  • Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Aβ. Proceedings of the National Academy of Sciences, 2001.
  • Muzumdar RH, et al. Humanin: a novel central regulator of peripheral insulin action (metabolic research literature).
  • Yen K, Lee C, Mehta H, Cohen P. The emerging role of the mitochondrial-derived peptide humanin in stress, metabolism and disease (review literature).

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need Humanin — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote